GB0722040D0 - Sustained release methotrexate formulations and methods of use thereof - Google Patents

Sustained release methotrexate formulations and methods of use thereof

Info

Publication number
GB0722040D0
GB0722040D0 GBGB0722040.3A GB0722040A GB0722040D0 GB 0722040 D0 GB0722040 D0 GB 0722040D0 GB 0722040 A GB0722040 A GB 0722040A GB 0722040 D0 GB0722040 D0 GB 0722040D0
Authority
GB
United Kingdom
Prior art keywords
methods
sustained release
formulations
release methotrexate
methotrexate formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0722040.3A
Other versions
GB2443738A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PROPRIUS PHARMACEUTICALS Inc
Original Assignee
PROPRIUS PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PROPRIUS PHARMACEUTICALS Inc filed Critical PROPRIUS PHARMACEUTICALS Inc
Publication of GB0722040D0 publication Critical patent/GB0722040D0/en
Publication of GB2443738A publication Critical patent/GB2443738A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB0722040A 2006-11-09 2007-11-09 A sustained release methotrexate composition and methods of use thereof Withdrawn GB2443738A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85822006P 2006-11-09 2006-11-09

Publications (2)

Publication Number Publication Date
GB0722040D0 true GB0722040D0 (en) 2007-12-19
GB2443738A GB2443738A (en) 2008-05-14

Family

ID=38858453

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0722040A Withdrawn GB2443738A (en) 2006-11-09 2007-11-09 A sustained release methotrexate composition and methods of use thereof

Country Status (1)

Country Link
GB (1) GB2443738A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157100B2 (en) * 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
AR039744A1 (en) * 2002-06-26 2005-03-09 Alza Corp METHODS AND DOSAGE FORMS TO INCREASE THE SOLUBILITY OF PHARMACOS COMPOSITIONS FOR CONTROLLED ADMINISTRATION
CA2494233A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050287213A1 (en) * 2004-06-28 2005-12-29 Wong Patrick S Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
US20050287214A1 (en) * 2004-06-28 2005-12-29 Ayer Atul D Squeeze controlled oral dosage form

Also Published As

Publication number Publication date
GB2443738A (en) 2008-05-14

Similar Documents

Publication Publication Date Title
ZA200707440B (en) Compositions and methods of making sustained release liquid formulations
HK1213814A1 (en) Diclofenac formulations and methods of use
EP1883406A4 (en) Compositions and methods for the sustained release of beta-alanine
EP2043647A4 (en) Controlled release formulations and associated methods
IL216401A0 (en) Sustained release of antinfectives
IL184735A0 (en) Pharmaceutical formulations and methods of use
PT1931315E (en) Sustained release formulations of nalbuphine
IL179991A0 (en) Modified release formulation of memantine
EP2024476A4 (en) Compositions comprising low-dp polymerized surfactants and methods of use thereof
IL198397A0 (en) Anilinopiperazine derivatives and methods of use thereof
EP1909644A4 (en) Inserter and methods of use
IL184563A (en) Pharmaceutical foam formulations and their uses
IL214617A0 (en) Use of controlled release formulations of octreotide
EP2021455A4 (en) Cytoblock preparation system and methods of use
IL184460A0 (en) Sustained release pharmaeutical formulations
HK1103023A1 (en) Sustained release formulations
EP2023718A4 (en) Creatine-ligand compounds and methods of use thereof
IL193693A0 (en) Purine compounds and methods of use thereof
IL194028A0 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
EP2160183A4 (en) Extended release formulations comprising quetipine and methods for their manufacture
IL178383A0 (en) Delayed release formulations of 6-mercaptopurine
EP1976488A4 (en) Sustained release compositions of alfuzosin
ZA201004489B (en) Release agent formulas and methods
EP2021448A4 (en) Compositions comprising low-dp polymerized surfactants and methods of use thereof
ZA200907727B (en) Cinnamaldehyde formulations and methods of use

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)